Fig. 6: Irigenin relived mouse CCl4-induced hepatic fibrosis.
From: FN-EDA mediates angiogenesis of hepatic fibrosis via integrin-VEGFR2 in a CD63 synergetic manner
A Schematic representation of hepatic fibrosis induction in C57BL/6 mice and treated with irigenin. B Masson staining in mouse CCl4-induced fibrotic livers treated with irigenin (n = 3). (Analysis relative area of Masson staining. Data are shown as mean ± SEM; week 2: ns; week 4: *P = 0.0207; week 6: ***P = 0.0003; week 8: **P = 0.0087; week 10: ns; scale bar = 200 μm.) C Immunohistochemical analysis of α-SMA expression in mouse CCl4-induced fibrotic livers treated with irigenin (n = 3). (Data are shown as mean ± SEM. Week 2: ns; week 4: ***P = 0.0003; week 6: **P = 0.0019; week 8: *P = 0.0436; week 10: ns; scale bar = 200 μm.) D Immunohistochemical analysis of CD31 expression in mouse CCl4-induced fibrotic livers treated with irigenin. Irigenin reduced CD31 expression in liver during hepatic fibrosis (n = 3). (Data are shown as mean ± SEM; week 2: ns week 4: *P = 0.0235; week 6: *P = 0.0169; week 8: *P = 0.0160; week 10: ns; scale bar = 200 μm.) E Transmission electron microscope (TEM) showing the hepatic sinusoids in the liver tissues. (Short arrows: LSEC fenestrae; long arrows: basement membrane; scale bar = 10 μm).
